MX2022004972A - Quimica de conjugacion novedosa para el anticuerpo catalitico 38c2. - Google Patents

Quimica de conjugacion novedosa para el anticuerpo catalitico 38c2.

Info

Publication number
MX2022004972A
MX2022004972A MX2022004972A MX2022004972A MX2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A
Authority
MX
Mexico
Prior art keywords
antibody
catalytic
anttibody
lys99
conjugation chemistry
Prior art date
Application number
MX2022004972A
Other languages
English (en)
Inventor
Christoph Rader
Dobeen Hwang
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2022004972A publication Critical patent/MX2022004972A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona el anticuerpo catalítico 38C2 modificado con arilación del residuo de lisina reactivo (Lys99). El residuo Lys99 se arila con un compuesto de heteroaril metilsulfonilo tal como metilsulfona feniloxadiazol (MS-PODA). La invención también proporciona agentes conjugados con anticuerpos (por ejemplo, conjugados de fármacos y anticuerpos) que contienen un resto de agente que está conjugado de forma específica del sitio con 38C2 a través de un compuesto de metilsulfonilo. Además, en la invención se proporcionan métodos para preparar los agentes conjugados con anticuerpos y aplicaciones terapéuticas de los agentes conjugados con anticuerpos.
MX2022004972A 2019-10-23 2020-10-15 Quimica de conjugacion novedosa para el anticuerpo catalitico 38c2. MX2022004972A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962925051P 2019-10-23 2019-10-23
PCT/US2020/055768 WO2021080846A1 (en) 2019-10-23 2020-10-15 Novel conjugation chemistry for catalytic anttibody 38c2

Publications (1)

Publication Number Publication Date
MX2022004972A true MX2022004972A (es) 2022-07-19

Family

ID=75620018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004972A MX2022004972A (es) 2019-10-23 2020-10-15 Quimica de conjugacion novedosa para el anticuerpo catalitico 38c2.

Country Status (11)

Country Link
US (1) US20230012213A1 (es)
EP (1) EP4048311A1 (es)
JP (1) JP2022553415A (es)
KR (1) KR20220087519A (es)
CN (1) CN114846030A (es)
AU (1) AU2020369479A1 (es)
BR (1) BR112022007734A2 (es)
CA (1) CA3155908A1 (es)
IL (1) IL292440A (es)
MX (1) MX2022004972A (es)
WO (1) WO2021080846A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036449A2 (en) * 2006-06-29 2008-03-27 The Regents Of The University Of California Chemical antibodies for immunotherapy and imaging
WO2014144878A2 (en) * 2013-03-15 2014-09-18 The Scripps Research Institute Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof
ES2878008T3 (es) * 2015-09-17 2021-11-18 Scripps Research Inst Inmunoconjugados de dominio variable dual y usos de los mismos

Also Published As

Publication number Publication date
JP2022553415A (ja) 2022-12-22
BR112022007734A2 (pt) 2022-07-12
EP4048311A1 (en) 2022-08-31
WO2021080846A1 (en) 2021-04-29
IL292440A (en) 2022-06-01
US20230012213A1 (en) 2023-01-12
CN114846030A (zh) 2022-08-02
KR20220087519A (ko) 2022-06-24
CA3155908A1 (en) 2021-04-29
AU2020369479A1 (en) 2022-05-26
AU2020369479A8 (en) 2022-06-09
WO2021080846A8 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
JP6608467B2 (ja) 生体直交型薬物活性化
Christie et al. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides
JP6533222B2 (ja) 新規の抗体−薬剤コンジュゲート及び治療におけるその使用
JP2024023543A (ja) カンプトテシンコンジュゲート
ES2758506T3 (es) Péptidos citotóxicos y conjugados de estos
WO2014081303A1 (en) Chemically cleavable group
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
MX2021015221A (es) Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
AR078470A1 (es) Anticuerpos que se unen especificamente al receptor epha2
PA8626201A1 (es) Conjugados de caliqueamicina
CY1117729T1 (el) Μεθοδοι για την παρασκευη κυτταροτοξικων συζευγματων μεϋτανσινοειδων και παραγοντων δεσμευσης κυτταρου
WO2016064749A3 (en) Antibody-drug conjugates and related compounds, compositions, and methods of use
SG10201810743WA (en) Conjugation methods
PE20110008A1 (es) Triazolopiridazinas como moduladores de quinasa
MX2022003740A (es) Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
PE20170917A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
RU2009117642A (ru) Применение спирооксиндоловых соединений в качестве терапевтических средств
GT200800277A (es) Derivados de leptomicina
ES2668645T3 (es) Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B
JP2017502047A5 (es)
ECSP088241A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
MX2022008381A (es) Compuestos relacionados con auristatina, compuestos conjugados de auristatina y metodos de uso de ellos.
WO2017180789A8 (en) Methods of treatment using chlorotoxin conjugates
PE20220764A1 (es) Conjugados de anticuerpo y farmaco